Survey-based Assessment of Hypothetical Alzheimer's Disease Treatments
Research type
Research Study
Full title
Survey-based Benefit-Risk Assessment of Hypothetical Alzheimer's Disease Treatments based on the Preferences of Patients, Care Partners, and Physicians in the US, UK and Germany.
IRAS ID
356360
Contact name
Matthew Quaife
Contact email
Sponsor organisation
Eli Lilly
Duration of Study in the UK
1 years, 0 months, 29 days
Research summary
The clinical course of Alzheimer’s disease (AD) involves progressive memory loss, behavioural decline, gait and motor disturbances, and declining ability to perform activities of daily living, eventually leading to complete dependence on a care partner, usually followed by nursing home care and eventually death.
Anti-amyloid antibody-based therapies have demonstrated significant delay in cognitive and functional progression. However, all currently available anti-amyloid therapies are associated with risks such as amyloid-related imaging abnormalities (ARIA). The benefit-risk profile of anti-amyloid antibody-based therapies depends on relative importance of the desired effects (slowed progression of cognition and functioning) and undesired effects (risk of ARIA). This study aims to determine whether the benefits of therapies outweigh their risk from the perspectives of patients, care partners, and physicians.
This study will employ preference elicitation methods to address the study objectives and to assess participants' preferences to hypothetical treatment profiles.
A web-based preference survey has been developed and pilot tested. All data will be electronically collected based on participant's entries into the survey and will take approximately 30 minutes to complete.
The survey will be administered to patients, care partners, and physicians in the United States (US), the United Kingdom (UK), and Germany. We are seeking NHS ethical approval specifically for conducting the survey with patients and care partners in the UK. The study design and materials have previously been approved by Salus IRB (Ref:24448).REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
25/NW/0143
Date of REC Opinion
13 Jun 2025
REC opinion
Further Information Favourable Opinion